



June 2025

NASDAQ: **IDYA**

IDEAYA Biosciences

Improving Lives
Through Transformative
Precision Medicines

Safe Harbor Statement

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. All statements other than statements of historical fact could be deemed forward-looking, assumptions, estimates or projections that are subject to change, including expectations regarding the clinical activity profile, potential clinical benefit and potential advantages of the Company’s clinical programs; the translation of preliminary clinical trial results into future clinical trial results; the enrollment of clinical trials; the potentially addressable patient population for the Company’s programs; any expectations regarding the Company’s target discovery platform or new target validation efforts as creating opportunities for research and development initiatives; any projections of financial information, market opportunities, cash runway or profitability, including the estimated funding of operations into 2029; any statements about historical results that may suggest trends for the Company’s business; any statements of the plans, strategies, and objectives of management for development programs or future operations; any statements about the timing of preclinical research, clinical development, regulatory filings, regulatory approvals, manufacturing or release of data; any statements of expectation or belief regarding future events, potential markets dynamics, technology developments, or receipt of cash milestones, option exercise fees or royalties; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, serious adverse events, undesirable side effects or unexpected characteristics of drug development, the regulatory approval processes, the timing of regulatory filings, the challenges associated with the manufacturing and/or commercialization; timing of product launches, potential pricing and reimbursement; potential revenue, expected breakthrough, best or first-in-class or blockbuster status, regulatory landscape, economic conditions, competitive landscape, the Company’s ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 and any current or periodic reports filed with the SEC. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company’s expectations.

Other

This presentation concerns anticipated products that are under clinical investigation and which have not yet been approved for marketing by the FDA or any other country regulatory authority. These anticipated products are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.


Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. The Company has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, the Company’s own internal estimates and research have not been verified by any independent source.

IDEAYA and the IDEAYA logo are trademarks of IDEAYA Biosciences, Inc. All other trademarks used herein are the property of their respective owners.

IDEAYA Vision to Build Industry Leading Precision Medicine Oncology Company

Improving Lives through Transformative Precision Medicines

Our mission is to advance the discovery, development, and commercialization of transformative precision medicines to address unmet medical needs in cancer



Potential First-in-Class Pipeline

6 Clinical Stage (5 SM & 1 ADC)

3 IND-Enabling (2 SM & 1 ADC)

Biomarker Populations


GNAQ/GNA11	DLL3
MTAP-Deletion	B7H3/PTK7
HRD/BRCA	8P11
MSI-High	

Potential First-in-Class Combos

PKC-cMET	WRN-PD1
MAT2A-PRMT5	PARG-TOP1
POLQ-PARP	MAT2A-TOP1

IDEAYA Precision Medicine Oncology Platform to Deliver First-in-Class Therapies

Fully-Integrated Target, Biomarker, Drug Discovery and Translational Capabilities



IDEAYA Biosciences Highlights

Leading Precision Medicine Oncology Biotechnology Company Advancing Potential First-in-Class Therapies

Target Milestone Guidance on Broad Pipeline of 6 Clinical & 3 Preclinical (IND-enabling) Programs:

PHASE 2/3	PHASE 1/2	PHASE 1/2	PRECLINICAL
DAROVASERTIB (PKC) <ul style="list-style-type: none"> Daro + Crizo 1L HLA-A2(-) MUM potential registrational Ph2/3 median PFS readout – by YE 2025 Daro + Crizo Ph2 1L MUM median OS readout at medical conference – H2 2025 Daro Ph2 Neoadjuvant UM clinical data update at medical conferences – mid-2025 and H2 2025 Daro Ph3 Neoadjuvant UM registrational trial initiation – H1 2025 	IDE397 (MAT2A) <ul style="list-style-type: none"> Phase 1/2 mono expansion ongoing IDE397 + Trodelvy® (Trop2-ADC) <ul style="list-style-type: none"> Expansion into NSCLC IDE397 + PRMT5 <ul style="list-style-type: none"> Wholly-owned clinical combo with IDE892 (IDEAYA PRMT5) – H2 2025 IDE849 / SHR-4849 (DLL3 ADC) <ul style="list-style-type: none"> Clinical data update at medical conference by Hengrui – Q3 2025 Combo initiation with IDE161 – H2 2025 	IDE275 / GSK959 (WERNER) <ul style="list-style-type: none"> Ongoing Phase 1 dose escalation IDE161 (PARG) <ul style="list-style-type: none"> Phase 1 mono dose optimization IDE161 + Merck's anti-PD-1, KEYTRUDA® (pembrolizumab) <ul style="list-style-type: none"> Phase 1 enrollment ongoing IDE161 + Topo1i-ADC <ul style="list-style-type: none"> Enable clinical combo with IDE849 – H2 2025 IDE705 / GSK101 (POL THETA) <ul style="list-style-type: none"> Phase 2 expansion (\$10M Milestone) 	NEXT GEN PROGRAMS <ul style="list-style-type: none"> IDE892 DC (MTA-cooperative PRMT5) IND submission – Mid-2025 IDE034 DC (B7H3/PTK7 Bi-Specific ADC) IND submission – H2 2025 IDE574 DC (KAT6/7) IND submission – H2 2025

Pharma Collaborations



~\$2B in potential milestones

Financials and Investor Relations

~\$1.05B to fund operations into 2029^{1, 2}

NASDAQ: IDYA

(1) Includes aggregate of approximately \$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025









(2) IDEAYA's Form 10-Q dated May 6, 2025, as filed with the U.S. Securities and Exchange Commission

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway NJ, USA

IND = Investigational New Drug, UM = Uveal Melanoma, MUM = Metastatic Uveal Melanoma, NSCLC = Non-Small Cell Lung Cancer, EC = Endometrial Cancer, UC = Urothelial Cancer, DC = Development Candidate, Daro = Darovasertib, Crizo = Crizotinib



IDEAYA's Potential First-in-Class Precision Medicine Oncology Pipeline

	Modality/Indication	Biomarker	Pre-clinical	IND Enabling	Phase 1	Phase 2	Potential Registrational	Program Goals / Achievements	Collaborations	Commercial (IDEAYA)
Darovasertib <i>PKC</i>	+cMET ¹ Combination 1L HLA-A2(-) MUM	GNAQ/11						Ph 2 (AA) / Ph 3 registrational trial ¹ – targeting median PFS readout by YE'25	 (4)	WW Commercial Rights
	(Neo)Adjuvant UM	GNAQ/11						Ph 2 clinical data update(s) – targeting mid'25 & H2'25 Ph3 Neoadj. UM registrational trial initiation ² – H1'25		
	cMET ¹ Combination MUM	GNAQ/11						Ph 2 OS 1L MUM readout – targeting H2'25 HLA-A2(+) Phase 2 clinical trial ³	 (4)	
IDE397 <i>MAT2A</i>	Monotherapy Solid Tumors	MTAP						Ongoing Phase 2 expansion in MTAP urothelial and lung cancer		WW Commercial Rights
	Combination UC and NSCLC	MTAP						Targeting Phase 1/2 IDE397 + Trodelvy® expansion into NSCLC	 (5)	
IDE849 (SHR-4849) <i>DLL3 ADC</i>	SCLC, Neuroendocrine Tumors	DLL3						Clinical data update at medical conference – Q3'25 Combination initiation with IDE161 – H2'25	 (6)	Worldwide Rights Outside of Greater China
IDE275 (GSK959) <i>Werner Helicase</i>	Solid Tumors	High-MSI						Ongoing Phase 1 Trial in MSI-High Solid Tumors	 (7)	50% US Profits and 20% costs
IDE161 <i>PARG</i>	Monotherapy Solid Tumors	HRD						Ongoing Phase 1 monotherapy dose optimization		WW Commercial Rights
	Combination Endometrial Cancer	High-MSI, MSS						Ongoing Phase 1 IDE161 + KEYTRUDA®	 (8)	
IDE705 (GSK101) <i>Pol Theta Helicase</i>	+Niraparib Combo Solid Tumors	HR Mutations						Targeting Phase 2 Expansion (\$10M Milestone)	 (7)	Global Royalties
IDE892 <i>PRMT5^{MTA}</i>	Combination Solid Tumors	MTAP						Targeting IND Submission – Mid-Year 2025 Enable wholly-owned combination with IDE397 – H2'2025		WW Commercial Rights
IDE034 <i>B7H3/PTK7 BsADC</i>	Solid Tumors	B7H3/PTK7						Targeting IND Submission – H2'25	 (9)	WW Commercial Rights
IDE574 <i>KAT6/7</i>	Solid Tumors	8p11						Targeting IND Submission – H2'25		WW Commercial Rights
Platform	Solid Tumors	Defined Biomarkers						Multiple Potential First-in-Class Programs Advancing		WW Commercial Rights

(1) Integrated Phase 2/3 enables potential Accelerated Approval (AA, Phase 2) and potential Full Approval (Phase 3) based on FDA Type C Meeting Q1 2023

(2) Phase 3 randomized registrational trial enables potential approval based on FDA Type C Meeting Q3 2024

(3) Targeting enrollment of additional HLA-A2(+) patients in ongoing IDE196-001 Phase 2 clinical trial

(4) Pursuant to Pfizer Clinical Trial Collaboration and Supply Agreements for Darovasertib/Crizotinib Combination; IDEAYA retains all Darovasertib Commercial Rights

(5) Pursuant to Gilead Clinical Study Collaboration and Supply Agreement for IDE397 + Trodelvy®, a Trop-2 directed antibody-drug conjugate (ADC); the Company will sponsor the study and Gilead will provide Trodelvy at no cost. Gilead retains all commercial rights to Trodelvy.

(6) Pursuant to exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd for worldwide rights outside of Greater China

(7) Pursuant to GSK Collaboration, Option and License Agreement: Polθ: Global Royalties; WRN: 50/50 US Profits + ex-US Royalties

(8) Pursuant to Merck Clinical Trial Collaboration and Supply Agreement for IDE161 + Keytruda®, an anti-PD-1 therapy; the Company will sponsor the study and Merck will provide Keytruda at no cost

(9) Pursuant to exclusive worldwide licensing and option agreement with Biocytogen


MAT2A = Methionine Adenosyltransferase 2a, MTAP = Methylthioadenosine Phosphorylase, MTA = Methylthioadenosine, PRMT5 = Protein Arginine Methyltransferase 5, PARG = Poly (ADP-ribose) Glycohydrolase, WRN = Werner Helicase, Polθ = DNA Polymerase Theta, HRD = Homologous Recombination Deficiency, MSI = Microsatellite Instability, PKC = Protein Kinase C, MUM = Metastatic Uveal Melanoma, UM = Uveal Melanoma, Crizo = Crizotinib, UC = Urothelial Cancer, NSCLC = Non-Small Cell Lung Cancer, WW = Worldwide, HLA-A2(-) = HLA-A2*02:01 Negative; HLA-A2(+) = HLA-A2*02:01 Positive, DC = Development Candidate, TOP1i = Topo-I-Payload, BsADC = Bispecific Antibody Drug Conjugate

 = Target Program Milestones

Darovasertib: Potential to Broadly Impact Uveal Melanoma (UM)

Potential First-in-Class and Best-in-Class in (Neo)adjuvant UM and Metastatic UM (MUM)

Mutations in GNAQ / GNA11 activate PKC Signaling, a genetic driver of Uveal Melanoma




Darovasertib is an oral, potent and selective PKC inhibitor GNAQ or GNA11 (~95%) and other upstream mutations activate PKC signaling in UM and MUM patients

UM is typically treated with radiation and/or enucleation, with no approved systemic therapies for Neoadjuvant UM

MUM occurs in approximately 50% of UM patients and predominantly as liver metastasis in ~90% of MUM patients, with no approved therapies for HLA-A*02:01 negative MUM

Daro Mono Rationale in Primary UM

Single Agent Daro Induces Tumor Regression
Uveal Melanoma Xenograft (92.1 mutant GNAQ)




Van Raamsdonk, CD, et. al, Nature 2009; Van Raamsdonk CD, et. al, NEJM 2010; Piperno-Neumann S, et. al, J Clin Oncol 2014

Darovasertib + Crizotinib (Daro + Crizo) Combo Rationale for Use in MUM



Daro Phase 1 Monotherapy Efficacy Association with cMET Expression




Ph 1 Clinical Outcomes

PD=Progressive Disease, SD=Stable Disease, PR=Partial Response

IDEAYA Data, AACR 2021

Activation of PKC and cMET Pathways with Observed cMET Overexpression in MUM Liver Metastases



Darovasertib and Uveal Melanoma Patient Journey

High Unmet Need and Multiple First-Line Opportunities in UM and MUM¹

+95% of UM patients harbor GNAQ/GNA11 mutation

Uveal Melanoma Patient Journey

	Neoadjuvant UM	Adjuvant UM	MUM
HLA-A2-Negative ²	No Approved Therapies Daro: Phase 3 Enucleation Cohort	No Approved Therapies Daro: Phase 2	No Approved Therapies Daro + Crizo (HLA A2-) Phase 2/3 Registrational Trial
HLA-A2-Positive ²			Daro + Crizo (HLA A2+) Target NCCN / Compendia Listing
Target Treatment Duration	6 months	≥6 months	mPFS + ~3 months
Target Clinical Endpoints	Eye Preservation, Proportion of patients with BCVA 15-letter loss, No detriment to EFS	Relapse Free Survival	ORR, mPFS, mOS
Annual Incidence ³	~12K	~12K	~4-5k

(1) No approved systemic therapies in multiple UM and MUM indications across the patient journey


(2) ~70% HLA-A*02:01-negative and ~30% HLA-A*02:01-positive frequency observed based on IDEAYA Clinical Study Data (n=170)

(3) Annual incidence for North America, Europe and Australia (as applicable), based on market research analysis

UM = Uveal Melanoma, MUM = Metastatic Uveal Melanoma, BCVA = Best Corrected Visual Acuity ORR = Overall Response Rate, mPFS = Median Progression Free Survival, mOS = Median Overall Survival


Daro + Crizo Phase 2 Efficacy: First-Line MUM and Any-Line MUM

Compelling Overall Response Rate (ORR) by RECIST 1.1 Observed



Confirmed 45% ORR and 90% DCR

Response by RECIST 1.1 First-Line MUM	Evaluable (N=20)
Confirmed ORR (9/20)	45%
Tumor Shrinkage (19/20)	95%
>30% Tumor Shrinkage (12/20)	60%
Best Overall Response	
cPR (9/20)	45%
SD (9/20)	45%
DCR (18/20)	90%




Confirmed 30% ORR and 89% DCR

Response by RECIST 1.1 Any-Line MUM	Evaluable (N=63)
Confirmed ORR (19/63)	30%
Tumor Shrinkage (58/63)	92%
>30% Tumor Shrinkage (27/63)	43%
Best Overall Response	
cPR (19/63)	30%
SD (37/63)	59%
DCR (56/63)	89%

Median PFS in First-Line, Any-Line and Hepatic-Only MUM

Observed Compelling Median Progression Free Survival with Encouraging Trend



Darovasertib + Crizotinib Phase 2

Median Progression Free Survival

- First-Line (n=20): 7.1 months
- Any-Line (n=63): 6.8 months
- Hepatic-Only (n=19): 11.0 months

Treatment Duration – Observations

- ~50% of patients treated > 6 months
- ~30% of patients treated > 1 year


Review of Published Clinical Data in MUM

	Darovasertib + Crizotinib	Cabozantinib Mono / Crizotinib Mono	Selumetinib + DTIC	Ipi + Nivo	Tebentafusp
Target / Mechanism	PKC + cMET	cMET	MEK + Chemotherapy	CTLA4 + PD-1	HLA-A2-0201 Bi-Specific
Study Name(s)	NCT03947385	A091201 ¹ / NCT05063058 ²	NCT01974752 ³	NCT02626962 ⁴	IMCgp100-102 ⁵
Population	1L/2L/3L+ MUM (n=63)	1L+ MUM (n=31) / 1L (n=6) 2L (n=1) MUM	1L+ MUM (n=97)	1L MUM (n=52)	2L+ MUM (n=127)
Patient Selection	NA	NA / MET Overexpression	NA	NA	HLA-A2-positive
Drug Form	Oral Tablets	Oral Capsules	Oral Capsules + chemo	IV infusion	IV Infusion (Weekly)
Tolerability (Grade ≥3 Drug-Related AE)	31%	51.6% / NA	63% (All Cause)	58%	46.5%
% of Patients with Tumor Shrinkage	First-Line = 95% / Any-Line = 92% / Hepatic Only = 100% ⁶	23% ⁷ / NA	35% ⁷	27% ⁷	44% ⁷
Confirmed ORR% (by RECIST 1.1)	First-Line = 45% / Any-Line = 30% / Hepatic Only = 37% ⁶	0% / 0%	3%	11.5% (not confirmed ORR)	4.7%
Median PFS	First-Line: 7.1 months / Any-Line: 6.8 months / Hepatic-Only: 11.0 months ⁶	2 months / NA	2.8 months	3 months	2.8 months

Note: these data are derived from different clinical studies, with differences in study design and patient populations. No head-to-head studies have been conducted. (1) Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201); Clin Cancer Res 2020;26:804–11 (2) European Journal of Cancer, Leyraz, et. al, 2022; 146-155 (3) Journal of Clinical Oncology, Carjaval, et. al, 2018; 1232-1239 (4) ASCO 2021, Piulats, J, et. al, Ipi = Ipilimumab, Nivo = Nivolumab, ORR% did not require PR/CR confirmation (5) Based on Immunocore reported 2L+ study data (to reflect comparative patient population) and by independent review and ORR% was with confirmed PRs (6) ESMO 2023 Proffered Presentation McKean, M, et al: Preliminary analysis of unlocked database as of 08/22/2023 by investigator review; data cutoff based on treatment Day 1 of Cycle 1 (C1D1) as of 9/22/2022 (7) Estimated from Waterfall plot

Darovasertib Neoadjuvant Therapy: Ph2 Company Sponsored & Ph2 IST UM Trials

61% (19 of 31) Observed Eye Preservation and 49% (24 of 49) with $\geq 30\%$ Tumor Reduction*



IDEAYA Data: Enrollment cut-off date of 13May24, and results as of 15Aug2024 (based on preliminary analysis of unlocked database for Ph2 company sponsored patients enrolled up to 13May2024); Ph2 IST as of 14May2024 [ASCO 2024 Oral Presentation]

*Ocular tumor size measured by the product of diameters (longest basal diameter x tumor thickness); **Based on clinical data correlating ocular tumor shrinkage with eye preservation and vision from darovasertib treatment in UM. Clinical data provided in FDA briefing book for FDA Type C meeting


IST = Investigator Sponsored Trial




Darovasertib Ph2/3 Registrational Trial Designs in MUM & Neoadjuvant UM

Broad opportunity to address unmet need in MUM and Save the Eye and Protect Vision in Neoadjuvant UM

Metastatic Uveal Melanoma Ph2/3 Registrational Trial¹



Neoadjuvant Uveal Melanoma Ph3 Registrational Trial



Primary Endpoints

- **Cohort 1:** Vision Preservation (Proportion with BCVA \geq 15 letters loss)
- **Cohort 2:** Eye Preservation Rate

Secondary Endpoints

- **Cohort 1:** Proportion with clinically significant macular edema; Proportion with VA 20/200 or worse; Radiation reduction
- **Cohorts 1 & 2:** ORR (\geq 20% ocular tumor shrinkage by product of diameters); No detriment to Event Free Survival (EFS)

FDA ► Orphan Drug Designation in UM³; Fast Track Designation in MUM; Breakthrough Therapy Designation⁴

(1) Clinicaltrials.gov: NCT05987332

(2) Phase 2 study contemplates data set of n=200 patients randomized 2:1 with treatment arm at move forward dose in support of potential accelerated approval based on mPFS

(3) Orphan Drugs benefit from certain tax credits and may be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act

(4) Breakthrough therapy designation for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) for whom enucleation has been recommended

Δ Nested study to confirm move forward dose: (i) Daro 300 mg BID + Crizo 200 mg BID or (ii) Daro 200 mg BID + Crizo 200 mg BID


UM = Uveal Melanoma, MUM = Metastatic Uveal Melanoma, BCVA = Best Corrected Visual Acuity, ORR = Overall Response Rate, mPFS = Median Progression Free Survival, mOS = Median Overall Survival

MAT2A Inhibition is Synthetic Lethal with MTAP-Deletion


MAT2A

Strategies to address MTAP^{-/-} Prevalence in ~15% of all Solid Tumors

MTAP-MAT2A Synthetic Lethality Biology



Robust monotherapy activity in lung, urothelial and gastric PDX




IDE397: Phase 2 Potential First-in-Class MAT2A Inhibitor


~48k U.S. Annual Incidence in MTAP-Deletion NSCLC and Urothelial Cancer

High Unmet Need: No FDA-Approved Therapies for MTAP-Deletion Solid Tumors

U.S. Annual Incidence in Priority Tumor Types




U.S. Annual Incidence in Potential Expansion Tumor Types



(1) Estimated addressable patient population based on SEER 2024 incidence and MTAP-deletion frequency from TCGA PanCancer Atlas, including frequency of 26% in urothelial, 19% in squamous NSCLC, 11% in adeno NSCLC, 21% pancreatic, 14% head and neck, 10% gastric, and 28% squamous esophageal cancers.
NSCLC = Non-Small Cell Lung Cancer

IDE397 Phase 1 Clinical Efficacy in MTAP-Deletion NSCLC & UC

Best Response by RECIST 1.1 at 30mg QD Phase 2 expansion dose¹



Efficacy by RECIST 1.1¹

Evaluable Pts	27
Best Response, n (%)	
CR	1 (4)
PR	8 (30)
SD	16 (59)
PD	2 (7)
ORR, n (%)	9 (33)
Confirmed, n ^{^^}	9
ORR, n (%), by Tumor (n)	
Squam NSCLC (8)	3 (38)
Adeno NSCLC (9)	2 (22)
Urothelial (10)	4 (40)
DCR, n (%)	25 (93)

(1) Evaluable Patients: Treated with ≥1 cycle (21 days) of IDE397 at the 30 mg expansion dose and with ≥1 post-baseline scan(s); # Patient received less than 75% of planned dosing prior to the first scan due to unrelated AEs in cycle 2; ^ Response evaluation by central review; ^^ PR with -100% best response had complete resolution of the target lesion; + patient still on treatment as of cut-off date. Data from an unlocked, unverified database as of 22AUG2024 data cut off; two patients confirmed response after the data cut. CR = Complete Response, PR = Partial Response, SD = Stable Disease, PD = Progressive Disease, ORR = Overall Response Rate, DCR = Disease Control Rate, c = Confirmed, NSCLC = Non-Small Cell Lung Cancer, UC = Urothelial Carcinoma, Squam = Squamous, Adeno = Adenocarcinoma, Pts = patients

IDE397 Phase 1/2 Clinical Development Plan in MTAP-Deletion Solid Tumors

Clinical Strategic Focus on High Conviction Rational Combinations


IDE397 – Clinical Profile

Exposure-Dependent
Pharmacokinetic (PK) Profile with
low $C_{max}:C_{min}$

Robust Pharmacodynamic (PD)
Response observed

Monotherapy Expansion
demonstrated clinical efficacy
with Responses in Multiple High-
Priority Tumor Types in Dose
Expansion, including a Complete
Response

IDE397 is strategically well positioned to evaluate both monotherapy and clinical combinations in MTAP-deletion solid tumors





(1) Trodelvy[®] = Gilead's Trop-2 directed ADC
(2) UC = Urothelial Cancer, NSCLC = Non-Small Cell Lung Cancer
(3) IDE892, IDEAYA PRMT5 inhibitor in IND-enabling studies

IDE849 (SHR-4849): Phase 1 DLL3 TOP1i ADC

First-in-Class Potential and Targeting Lineage Survival Oncogene Activity

IDE849 (SHR-4849) potential first-in-class/best-in-class

The SCLC lineage survival oncogene, ASCL1, directly promotes DLL3 expression




- DLL3 expression driven by the tumor-essential ASCL1 TF
- Humanized antibody with strong affinity and high selectivity
- Proprietary TOP1i payload (~4,000 patients treated)
- Internalization-dependent cleavable linker
- Optimized DAR value of 8
- High plasma stability
- Estimated high therapeutic index


DLL3 = Delta-Like Ligand 3, ADC = Antibody Drug Conjugate, TOP1i = Topoisomerase I Inhibitor, DAR = Drug-to-Antibody Ratio, TF = Transcription Factor

Deep regressions in DLL3⁺ CDX/PDX with exceptional linker/payload stability in circulation

Deep regressions observed in DLL3⁺ SCLC



Limited to no payload deconjugation in vivo



Source: Hengrui Pharma
CDX = Cell Line-Derived Xenograft, PDX = Patient-Derived Xenograft, PK = Pharmacokinetics

DLL3 Expression is Upregulated in a Broad Range of Solid Tumor Types

>100k Potential Addressable Population in the US Alone


Table of DLL3 Upregulated Expression Solid Tumors

Tumor Type	US Incidence (2024), 000	DLL3 Expressed, %	Addressable US Population, 000
SCLC	33	85%	33.0 ¹
NETs	37	34.1%	12.6
NSCLC	202	11%	22.2
Melanoma	101	43%	43.4
Glioma	25	72-78%	18.8
RCC	82	7%	5.7
Thyroid	44	16%	7.0

¹Based on 100% as no need to stratify SCLC population

Source: SEER, Rojo, F., at al., Lung Cancer. 2020;147:237–243; Tanaka, K., at al., Lung Cancer. 2018 Jan:115:116-120; Yao, J., at al., The Oncologist, 2022, 27, 940–951; Ali, G., at al., Front. Oncol. 11:729765; Song, H., at al., Exp Ther Med 16: 53-60, 2018. Lozada JR, et al. Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer Res Commun. 2025 Feb 1;5(2):318-326. doi: 10.1158/2767-9764.CRC-24-0501

Addressable US Population: SCLC and NETs only 32%




IDE849 (SHR-4849): Potential First-in-Class with Preliminary Ph1 Clinical PoC

Phase 1 FIH Study of DLL3 Topo-1-Payload ADC in Pre-Treated SCLC Patients

Phase 1 Dose Escalation in China in Pre-Treated SCLC Patients¹

- **Preliminary Clinical PK Summary**
 - Dose dependent increase in exposure
 - Promising T-Ab to ADC ratio
- **Preliminary Clinical Efficacy Summary²**
 - 8 of 11 evaluable SCLC patients observed a partial response by RECIST 1.1, resulting in a ~73% ORR (confirmed and unconfirmed, all unconfirmed PRs remain confirmable)
- **Preliminary Clinical Safety Summary**
 - TRAEs were largely Grade 1 or 2
 - No AE leading to discontinuation (related or unrelated)
 - Maximum tolerated dose has not yet been reached
 - Most commonly observed TRAEs: white blood cell count decreased, anemia, neutrophil count decreased, nausea and platelet count decreased

Tumor Reductions and Responses seen in most evaluable subjects after IDE849 Treatment¹



(1) All unconfirmed responses pending further evaluation

(2) Clinical efficacy summary at therapeutic dose levels

Source: Hengrui Pharma. Data Cut off Dec 10, 2024.

ADC = Antibody Drug Conjugate, SCLC = Small Cell Lung Cancer, T-Ab = Total Antibody, PR = Partial Response, u = Unconfirmed, c = Confirmed

IDE849 (SHR-4849): Potential First-in-Class with Preliminary Ph1 Clinical PoC


Pre-Treated SCLC Patient Case Study and Preliminary IDEAYA Clinical Development Plan

Case Example in Phase 1 FIH Dose Escalation


A 70-year-old male with extensive stage SCLC who had failed prior PD-L1 and platinum doublet treatment

The subject was treated with IDE849 and achieved PR at Week 6 with a 70.6% reduction in the large mediastinal tumor mass

Baseline




Week 6



IDE849 Phase 1/2 Clinical Development Plan

- IDE849 Monotherapy Dose Escalation and Expansion



- IDE849 Combination with IDE161/PARG



Preliminary Clinical Strategy:

- Potential monotherapy path in 2L plus SCLC
- Evaluate clinical combinations, including with SOC, in 1L SCLC
- Evaluate NETs as monotherapy, including potential basket trial
- Target to enhance durability with IDE849 + IDE161/PARG combo


IDE275 (GSK959): Phase 1 Werner Helicase Non-Covalent Inhibitor

Potential Best-in-Class Profile with Distinct Binding Mode


AACR

New Drugs on the Horizon
AACR 2025, Chicago, IL
Oral Presentation


WRN Helicase Activity is Essential for Survival of MSI-high/dMMR Cancer Cells




Unique IDE275/GSK959-bound helicase conformation can overcome intrinsic and acquired resistance to current clinical WRNi



IDE275 (GSK959) has distinct binding mode vs current clinical compounds- no interaction with C727




MSI-H Chemo Refractory Gastric Cancer PDX (GA6894)



WRNi_2 = in vivo tool analog of IDE275/GSK959

SW48 (MSI-H CRC)



IDE275 (GSK959): Phase 1 Werner Helicase Non-Covalent Inhibitor



Phase 1 Clinical Development Plan in MSI-High Solid Tumors

IDE275 (GSK959) Werner Helicase Inhibitor

- IDE275 (GSK959) has demonstrated robust and selective synthetic lethality preclinically in the high microsatellite instability (MSI-High) biomarker setting
- Phase 1 clinical trial enrolling patients having tumors characterized by MSI-High (NCT06710847)

Werner Clinical Development Plan

PART 1: Monotherapy Dose Escalation

Monotherapy IDE275 (GSK959)

- ≥18 years old
- >3 months life expectancy
- dMMR/MSI-H tumor
- Advanced (unresectable/metastatic or recurrent)
- Must have exhausted SOC

PART 3: Combination Dose Escalation

Combo IDE275 (GSK959) + PD-1

- ≥18 years old
- >3 months life expectancy
- dMMR/MSI-H tumor
- Advanced (unresectable/metastatic or recurrent)
- Must have exhausted SOC

PART 2: Monotherapy Dose Expansion

- Histological diagnosis of CRC or ECH

GSK Strategic Partnership: 50/50% US Profit Share and ex-US Royalties, ~\$1B Milestones, incl. up to \$20M Preclinical / Ph1 Clinical; Cost Share 80% (GSK) / 20% (IDEAYA); Potential Combination with GSK's Jemperi™, a PD-1 IO Agent

IDE161: Potential First-in-Class Phase 1 PARG Inhibitor


SL with replication stress; broad potential in combination with TOP1i-ADCs

PARGi disrupts DDR and replication fork fidelity


PARG inhibition is synthetic-lethal with oncogene-induced replication stress

➤ **PARP1 initiates DDR**


➤ **PARG resolves DDR**



➤ **PARG inhibition promotes death by mitotic catastrophe**




- Replication stress triggers replication fork reversal
- PARG is required for replication fork restart



Adapted from Pillay et al. Cancer Cell, 2019

IDE161/TOP1i interaction underpins ADC combination opportunity

Dual inhibition of TOP1 & PARG produces toxic DNA-protein crosslinks







Fam-trastuzumab deruxtecan/IDE161 combination POC

NSCLC HER2+

Colorectal HER2 Low

SLC HER2 Low




IDE705 (GSK101): Potential First-in-Class Ph1 Pol Theta Helicase Inhibitor

Phase 1 in Combination with Niraparib (PARPi)




Pol Theta Helicase *In Vivo* Activity

IDE705(GSK101) + PARPi



BRCA 1/2 Clinical Reversions

BRCA Reversions Mediated by MMEJ



Clinical Development Strategy

Pol Theta Helicase Inhibitor



PARP Inhibitor

Pol Theta Helicase Inhibitors Disrupt MMEJ Alternative DNA Damage Repair:

- Inhibit DSB Repair by MMEJ
- Dysregulate Replication Fork Stabilization

Potentiate PARPi Efficacy

Prevent PARPi Resistance

Overcome PARPi Resistance


Potential Clinical Opportunities

GSK Strategic Partnership: Global Royalties with GSK covering all Costs, ~\$1B Milestones, incl. up to \$20M Preclinical / Ph1 Clinical Potential Combination with GSK's Zejula™, a PARP Inhibitor


Development Candidates: Targeting INDs Mid-2025 to H2-2025

IDE892: PRMT5ⁱMTA


MTA-templated target binding



Robust pathway modulation




Exceptional IDE397 combination benefit (MTAP^{-/-} CDX)



Wholly-owned MAT2a/PRMT5 combination for MTAP-deletion


IDE034: B7H3/PTK7 Bispecific ADC

α B7-H3 α PTK7



- Enhanced tumor versus normal cell binding
- Enhanced internalization efficiency
- Substantial double-positive disease population¹


Monotherapy regressions observed in multiple models (B7H3/PTK7 dual positive PDX)



Dual tumor-antigen targeting to maximize SM combination benefit (IDE161)


IDE574: Dual KAT6/KAT7 Inhibitor

Dual potency design challenge




- KAT7 pocket (270 Å³)
- KAT6 pocket (614 Å³)
- Residue differences

Strong and selective cellular target binding by IDE574 (BRET assay)



Durable anti-tumor activity PDX ST941 (HR+ mBC, ESR1 Y537S)



Potent pathway modulation delivers broad opportunity to drug lineage-addiction

Building a Fully-Integrated Biotech in Precision Medicine Oncology

Foundational Potential First-in-Class Clinical Pipeline and Drug Discovery Platform



Darovasertib Registration-Enabling Trial with Potential Accelerated Approval in HLA-A2(-) MUM and Ph3 registrational trial targeted in Neoadjuvant UM is tractable for commercial execution and provides path to potential product revenue to reinvest in broad *first-in-class* pipeline

Potential First-in-Class Precision Medicine Oncology Pipeline, including Darovasertib (Ph2/3), IDE397 (Ph 2), IDE849 (Ph1), IDE275 / GSK959 (Ph 1), IDE161 (Ph 1), IDE705 / GSK101 (Ph 1), IDE892 (IND-enabling), IDE034 (IND-enabling), and IDE251 (IND-enabling)

Strong Balance Sheet with ~\$1.05B⁵ and opportunity for milestone payments with cash runway into at least 2028

Pharma Collaborations including Pfizer, Gilead, Merck, Hengrui, and GSK partnership with ~\$2 billion³ in potential milestones

(1) Clinical Trial Collaboration and Supply Agreements, independently with Pfizer (Darovasertib + Crizotinib), Gilead (IDE397 + Trodelvy®), and Merck (IDE161 + KEYTRUDA®); IDEAYA retains all commercial rights to its products

(2) IDE849 (SHR-4849): DLL3 Top1i Antibody Drug Conjugate. Exclusive license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd for worldwide rights outside of Greater China

(3) IDE705 (GSK101) Pol Theta Program Cost Share = 100% GSK with ~\$1B Milestones and WW Royalties; IDE275 (GSK959) Werner Helicase Program Cost Share = 80% GSK / 20% IDEAYA with ~\$1B Milestones, 50/50 US Profit Share and Ex-US Royalties

(4) IDE034: B7H3/PTK7 Top1i Bispecific ADC development candidate. Exclusive worldwide licensing and option agreement with Biocytogen

(5) Includes aggregate of approximately \$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025